DEXTROSE AND SODIUM

The contract pertains to the procurement of Dextrose 5% in 0.2% Sodium Chloride Injection, packaged in 250 mL bags with a unit of issue of one PG consisting of 24 bags, identified by NSN 6505-01-331-8944 and manufacturer part number NDC00264-7616-20 from B. BRAUN MEDICAL INC. The product is regulated by the FDA, and delivery must occur within 20 days after order placement to the consignee at Building 860, Depot Storage and Receiving Warehouse, Fort Irwin, California, under FOB Destination terms with zero variance permitted in quantity. The item has a non-extendable shelf-life of 24 months as a TYPE I (CODE M) product, and all packaging must strictly adhere to MIL-STD-2073-1E for protective packaging and preservation, while labeling and marking must conform to Medical Marking Standard No. 1, which supersedes MIL-STD-129 for medical items, though MIL-STD-129 remains applicable for hazardous and radioactive material markings. Hazard communication standards under 29 CFR 1910.1200 apply to any hazardous materials, and removal of government identification from non-accepted supplies is required. The solicitation, issued under SPE2DP-26-T-3555 with a response deadline of June 2, 2026, is administered by the Department of Defense’s Medical Supply Chain Pharm FSA and requires electronic submission via the DLA Internet Bid Board System only. Contract performance is governed by a robust set of FAR and DFARS clauses including those pertaining to combating trafficking in persons, employment eligibility verification, sustainable products, hazardous material identification, cybersecurity safeguarding under NIST SP 800-171, and prohibitions on acquiring equipment from communist Chinese military companies or using mandatory arbitration agreements. Inspection and acceptance occur at the destination, and payment must be processed electronically through Wide Area WorkFlow. The contract includes multiple deviation-modified clauses with updated implementation dates through February 2026, and offerors must provide unique entity identifiers and accurately represent their small business status, including any joint venture participation. All documentation and compliance measures, including submission of required certifications and representations, are mandatory and must align with federal acquisition regulations, with no contract value disclosed due to incomplete pricing data